It could be that they are given options that vest in Dec of each year, and lots of people want the cash for shopping
It was good to see almost 400k shares traded today on an up day. A solid green week as well, let's hope it continues. Management said they expected the CHMP decision in Jan. Hopefully 24 Jan 2014 is a really good day for all of us.
We know approx. 150 million has been paid. This leaves 730 million which we can assume must be riding on approval. I'm guessing a big chunk is FDA but EMA should be respectable. Of course, we don't know how much of the deal is for trial cost reimbursement which I think is part of it.
As far as CHMP, it is a concern the 4th qtr has come and almost gone as management repeatedly stated 4th qtr. Still hopeful.
Don't think they ever gave out specifics, just general info on the total amount. I wonder how far ahead on the January meeting the agenda will come out?
Brand & Customer Manager, Oncology-PRO011087
We are seeking to appoint two (Senior) or Brand and Customer Managers who will be responsible for preparing the launches of our two pipeline products VYNFINIT (vintafolide), initially in platinum-resistant ovarian cancer, and MK-3475(anti-PD1), initially in metastatic melanoma, together with commercialising our in-line brand, EMEND. Both pipeline compounds have on-going clinical trials in lung cancer and programmes of research beyond these tumour types with significant additional revenue potential and high-priority in the Merck drug development portfolio. The successful individuals will be responsible for developing and implementing customer engagement, brand marketing and market access plans to ensure early scientific support for these innovations, compelling value propositions for the NHS that can secure funding and competitive differentiation vs existing SOC and other new launch products. Oncology is a technically complex and fast-moving scientific and clinical landscape with plenty of policy and media angles to be considered.
If you want to be part of something truly significant in Merck, and in the field of cancer treatment in the UK, then there is no better opportunity to develop your marketing career in the next 3 years and this is the commitment we are looking for from the successful candidates.
Develop Oncology Franchise marketing strategy and tactical plan:
Work with global marketing team, medical affairs and market access colleagues to develop and tailor the scientific platform, brand positioning, medical education programme and payer value proposition for VYNFINIT and MK-3475
Segment and prioritise customer base and develop sub-national plans to maximise launch effectiveness
Implement marketing plan for key hospital customers and NHS Management / payors to achieve KPIs including launch readiness metrics
Develop and implement promotional materials and educational programmes
Understand market, competitors and customer base in key tumour types to identify key customer needs and identify revenue opportunities
Collaborate and work closely with support functions to customise global materials to be appropriate to UK market.
Apparently the EMA is now publishing CHMP agendas. Vintafolide is not being discussed at this month's meeting...
Merry Christmas and Happy New Year! See you all in January.